Legend Biotech (LEGN) Prices 7.5M Share Offering at $40/sh

Pre-Open Stock Movers 12/15: (QNRX) (GMTX) (GRTX) Higher; (RBLX) (LESL) (MGNI) Lower (more...)

Pre-Open Stock Movers:

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) 61% HIGHER; announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with Orpharm LLC (Orpharm) for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease, for which there is currently no available treatment or cure.

Gemini Therapeutics Inc. (NASDAQ: GMTX) 34.8%... More

After-Hours Stock Movers 12/14: (GRTX) (CFVI) (DWAC) Higher; (LESL) (LEGN) (PK) Lower (more...)

After-Hours Stock Movers:

Galera Therapeutics (NASDAQ: GRTX) 13.7% HIGHER; BTIG upgraded from Neutral to Buy with a price target of $15.00.

CF Acquisition Corp. VI (NASDAQ: CFVI) 11% HIGHER; gains as Trump Media & Technology Group (NASDAQ: DWAC) has entered into a wide-ranging technology and cloud services agreement with Rumble Inc. Rumble is merging with SPAC CF Acquisition Corp. VI.

Leslies, Inc. (Nasdaq: LESL) 7.1% LOWER;... More

Legend Biotech (LEGN) Announces Proposed $300M Share Offering

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it intends to offer and sell $300.0 million of American Depositary Shares (ADSs), each representing two ordinary shares, in an underwritten public offering. All ADSs to be sold in the proposed offering will be offered by Legend Biotech. Legend Biotech also intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of ADSs sold in the public offering at the public offering... More